Company intelligence / Profile preview

Zhejiang JINJIA

Shaoxing/Xinchang, Zhejiang, Chinadnb.com ↗

Ownership: Private
Employees: ~3800
Development stage: Other

Overview

Zhejiang Jingxin Pharmaceutical has a broad commercial portfolio of finished dosage forms including generics such as simvastatin and sertraline hydrochloride. It also has innovative pipeline assets in CNS disorders at Phase II or earlier stages. Dimdazenil received approval in China in November 2023 for sleep disorders. Other pipeline assets target schizophrenia (Phase II), ulcerative colitis (Phase II), hyperlipidemia (Phase I), and Parkinson’s disease (Phase I)[7].

Therapeutic areas: GastroenterologyPsychiatryCardiovascularNeurology
Modalities: Small moleculeBiologicHerbal medicineOligonucleotideTraditional Chinese medicine (TCM)
Industry: Biotech

Partnerships

Collaborations with international companies/labs including Bio‑Pharm Solutions Co Ltd on JBPOS‑0101

Beyond the preview

Go deeper on Zhejiang JINJIA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang JINJIA.

Explore the full profile